RAMM Pharma Corp.
RAMM
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -11.53% | -8.26% | -28.13% | -5.53% | 44.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -11.53% | -8.26% | -28.13% | -5.53% | 44.46% |
| Cost of Revenue | -41.45% | -8.90% | -26.72% | 63.64% | 20.52% |
| Gross Profit | 70.89% | -6.90% | -31.79% | -1,407.13% | 219.49% |
| SG&A Expenses | -3.21% | 14.03% | -18.34% | -41.06% | 24.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -56.73% | -38.32% | -22.62% | 1.02% | 16.85% |
| Total Operating Expenses | -17.67% | 6.67% | -20.97% | -12.83% | 22.78% |
| Operating Income | 23.93% | -19.25% | 15.53% | 15.77% | -6.44% |
| Income Before Tax | 6.81% | -48.13% | -37.75% | 77.10% | 12.47% |
| Income Tax Expenses | -- | -- | -- | 12.70% | -- |
| Earnings from Continuing Operations | 6.81% | -48.13% | -37.75% | 77.05% | 12.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.81% | -48.13% | -37.75% | 77.05% | 12.47% |
| EBIT | 23.93% | -19.25% | 15.53% | 15.77% | -6.44% |
| EBITDA | 21.45% | -44.00% | 13.37% | 13.65% | -9.95% |
| EPS Basic | 6.15% | -50.70% | -40.59% | 76.44% | 10.96% |
| Normalized Basic EPS | 5.00% | -52.27% | -41.27% | 8.55% | 11.11% |
| EPS Diluted | 6.15% | -50.70% | -40.59% | 76.44% | 10.96% |
| Normalized Diluted EPS | 5.00% | -52.27% | -41.27% | 8.55% | 11.11% |
| Average Basic Shares Outstanding | -1.07% | -1.98% | -2.38% | -2.48% | -1.56% |
| Average Diluted Shares Outstanding | -1.07% | -1.98% | -2.38% | -2.48% | -1.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
